Boston Scientific Net Change in Cash decreased by 175.1% to -$504.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 260.5%, from $314.00M to -$504.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
A positive change indicates net cash generation, while a negative change indicates cash consumption for the period.
The total net increase or decrease in cash, cash equivalents, and restricted cash during the reporting period. It is the...
A fundamental liquidity metric used to compare cash management efficiency across all public companies.
net_change_in_cash| Q2 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $645.00M | $9.00M | -$1.64B | -$71.00M | -$363.00M | -$143.00M | $513.00M | -$77.00M | $1.44B | $565.00M | -$412.00M | -$2.04B | $314.00M | $735.00M | $671.00M | -$504.00M |
| QoQ Change | — | -98.6% | <-999% | +95.7% | -411.3% | +60.6% | +458.7% | -115.0% | >999% | -60.8% | -172.9% | -396.1% | +115.4% | +134.1% | -8.7% | -175.1% |
| YoY Change | — | — | — | -111.0% | +77.9% | -101.4% | — | — | +497.0% | +495.1% | -180.3% | <-999% | -78.2% | +278.4% | +132.8% | -260.5% |